158
Views
10
CrossRef citations to date
0
Altmetric
Review

Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening

, , &
Pages 537-547 | Published online: 12 Apr 2019

References

  • GuptaRSharmaKKGuptaBKGeographic epidemiology of cardiometabolic risk factors in middle class urban residents in India: cross-sectional studyJ Glob Health2015515016210.7189/jogh.05.010411
  • WilliamsBManciaGSpieringWESC Scientific Document GroupESC/ESH guidelines for the management of arterial hypertensionEur Heart J201820183930213104
  • World Health OrganisationAdherence to Long-Term Therapies: Evidence for ActionWHO200311 Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/Accessed August 2, 2018
  • KotsevaKWoodDDe BacquerDEUROASPIRE InvestigatorsEUROASPIRE IV: a European society of cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countriesEur J Prev Cardiol20162363664810.1177/204748731556940125687109
  • KhuntiKSeiduSKunutsorSDaviesMAssociation between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysisDiabetes Care2017401588159610.2337/dc16-192528801474
  • ParekhNAliKStevensonJMIncidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UKBr J Clin Pharmacol20188481789179710.1111/bcp.1361329790202
  • EgedeLEGebregziabherMDismukeCEMedication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvementDiabetes Care2012352533253910.2337/dc12-057222912429
  • HaynesRBMcDonaldHGargAXMontaguePInterventions for helping patients to follow prescriptions for medicationsCochrane Database Syst Rev2002CD00001112076376
  • NieuwlaatRWilczynskiNNavarroTInterventions for enhancing medication adherenceCochrane Database Syst Rev2014111732CD000011
  • GuptaPPatelPHorneRBuchananHWilliamsBTomaszewskiMHow to screen for non-adherence to antihypertensive therapyCurr Hypertens Rep2016181810.1007/s11906-015-0615-426694820
  • TomaszewskiMWhiteCPatelPHigh rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysisHeart20141001185586110.1136/heartjnl-2013-30506324694797
  • GBD 2016 Causes of Death CollaboratorsGlobal, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016Lancet20173901151121010.1016/S0140-6736(17)32152-928919116
  • World Health OrganisationGlobal report on diabetes2016 Available from: http://www.who.int/diabetes/global-report/en/Accessed October 3, 2018
  • ChoNHShawJEKarurangaSIDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045Diabetes Res Clin Pract201813827128110.1016/j.diabres.2018.02.02329496507
  • Diabetes fact sheetWorld Health Organization web site [Updated 2017]. Available from: http://www.who.int/news-room/fact-sheets/detail/diabetesAccessed Oct 3, 2018
  • Centers for Disease Control and PreventionNational Diabetes Statistics Report: Estimates of Diabetes and its Burden in the United States, 2014Atlanta (GA)US Department of Health and Human Services2014
  • KronishIMYeSAdherence to cardiovascular medications: lessons learned and future directionsProg Cardiovasc Dis20135559060010.1016/j.pcad.2013.02.00123621969
  • SjölanderMErikssonMGladerEThe association between patients’ beliefs about medicines and adherence to drug treatment after stroke: a cross-sectional questionnaire surveyBMJ Open20133e00355110.1136/bmjopen-2013-003551
  • DiasAPereiraCMonteiroMJSantosCPatients’ beliefs about medicines and adherence to medication in ischemic heart diseaseAten Primaria201446Suppl 510110610.1016/S0212-6567(14)70074-525476044
  • GuptaPMohamedAAPatelPHigh rates of non-adherence to antidiabetic, antihypertensive and lipid lowering treatment in patients with type 2 diabetes revealed liquid chromatography-tandem mass spectrometry (lc-ms/ms) urine analysisAtheroscler Suppl201834e210.1016/j.atherosclerosissup.2018.07.021
  • CohenJDBrintonEAItoMKJacobsonTAUnderstanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin usersJ Clin Lipidol2012620821510.1016/j.jacl.2012.03.00322658145
  • ChaudharyRGargJShahNSumnerAPCSK9 inhibitors: a new era of lipid lowering therapyWorld J Cardiol20179769110.4330/wjc.v9.i2.7628289523
  • GragnanoFConcilioCCesaroAP1513 Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapyEur Heart J201738134
  • SaborowskiMDölleMMannsMPLeitolfHZenderSLipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: effectiveness, therapy adherence and safety in a real world cohortCardiol J201825324110.5603/CJ.a2017.013729168543
  • FortinMBravoGHudonCVanasseALapointeLPrevalence of multimorbidity among adults seen in family practiceAnn Family Med2005322322810.1370/afm.272
  • CassellAEdwardsDHarshfieldAThe epidemiology of multi-morbidity in primary care: a retrospective cohort studyBr J Gen Pract201868e25110.3399/bjgp18X694949
  • WallaceESalisburyCGuthrieBLewisCFaheyTSmithSMManaging patients with multimorbidity in primary careBMJ201535017610.1136/bmj.h176
  • MarcumZAGelladWFMedication adherence to multidrug regimensClin Geriatr Med20122828730010.1016/j.cger.2012.01.00822500544
  • GuptaPPatelPŠtrauchBRisk factors for nonadherence to antihypertensive treatmentHypertension2017691113112010.1161/HYPERTENSIONAHA.116.0872928461599
  • NICE-The National Institute for Health and Care ExcellenceSimvastatinBNFBritish National Formulary – NICE web site [Updated 2019]. Available from: https://bnf.nice.org.uk/medicinal-forms/simv-astatin.html#PHP76700Accessed January 28, 2019
  • NICE-The National Institute for Health and Care ExcellenceEzetimibeBNFBritish national formulary – NICE web site [Updated 2019]. Available from: https://bnf.nice.org.uk/medicinal-forms/ezetimibe.htmlAccessed January 28, 2019
  • NICE-The National Institute for Health and Care ExcellenceSimvastatin with ezetimibeBNFBritish national formulary – NICE web site [Updated 2018]. Available from: https://bnf.nice.org.uk/medicinal-forms/simvastatin-with-ezetimibe.htmlAccessed August 9, 2018
  • ChowdhuryRKhanHHeydonEAdherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequencesEur Heart J2013342940294810.1093/eurheartj/eht29523907142
  • PolonskyWHHenryRRPoor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributorsPatient Prefer Adherence2016101299130710.2147/PPA.S10682127524885
  • IglayKCartierSERosenVMMeta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetesCurr Med Res Opin2015311283129610.1185/03007995.2015.105304826023805
  • LinLSunYHengBHChewDEKChongPMedication adherence and glycemic control among newly diagnosed diabetes patientsBMJ Open Diabetes Res Care20175e00042910.1136/bmjdrc-2017-000429
  • HongJSKangHCRelationship between oral antihyperglycemic medication adherence and hospitalization, mortality, and healthcare costs in adult ambulatory care patients with type 2 diabetes in South KoreaMed Care20114937838410.1097/MLR.0b013e31820292d121368684
  • LauDTNauDPOral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetesDiabetes Care2004272149215315333476
  • CurrieCJPeyrotMMorganCLThe impact of treatment noncompliance on mortality in people with type 2 diabetesDiabetes Care2012351279128410.2337/dc11-127722511257
  • KimYLeeJKangHParkSMEffect of medication adherence on long-term all-cause-mortality and hospitalization for cardiovascular disease in 65,067 newly diagnosed type 2 diabetes patientsSci Rep201881121901219710.1038/s41598-018-30740-y30111867
  • NaderiSHBestwickJPWaldDSAdherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patientsAm J Med2012125882.e1887.e110.1016/j.amjmed.2011.12.01322748400
  • KolandaiveluKLeidenBBO'GaraPTBhattDLNon-adherence to cardiovascular medicationsEur Heart J2014353267327610.1093/eurheartj/ehu36425265973
  • HoPMSpertusJAMasoudiFAImpact of medication therapy discontinuation on mortality after myocardial infarctionArch Intern Med20061661842184710.1001/archinte.166.17.184217000940
  • KimSShinDWYunJMMedication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medicationsHypertension20166750651210.1161/HYPERTENSIONAHA.115.0673126865198
  • VelliganDIWangMDiamondPRelationships among subjective and objective measures of adherence to oral antipsychotic medicationsPsychiatr Serv2007581187119210.1176/ps.2007.58.9.118717766564
  • HessLMRaebelMAConnerDAMaloneDCMeasurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measuresAnn Pharmacother2006401280128810.1345/aph.1H01816868217
  • MeddingsJKerrEAHeislerMHoferTPPhysician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin tossBMC Health Serv Res20121227010.1186/1472-6963-12-27022909303
  • ShiLLiuJFonsecaVWalkerPKalsekarAPawaskarMCorrelation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysisHealth Qual Life Outcomes201089910.1186/1477-7525-8-9920836888
  • MoriskyDEAngAKrousel-WoodMWardHJPredictive validity of a medication adherence measure in an outpatient settingJ Clin Hypertens (Greenwich)20081034835418453793
  • VoilsCIHoyleRHThorpeCTMaciejewskiMLYancyWSImproving the measurement of self-reported medication nonadherenceJ Clin Epidemiol20116425025410.1016/j.jclinepi.2010.07.01421194887
  • Medicines adherence (NICE guideline 76)NICE Web site [Updated 2009] Available from: https://www.nice.org.uk/guidance/CG76Accessed September 26, 2018
  • EwenSMeyerMRCremersBBlood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysisClin Res Cardiol20151041097110510.1007/s00392-015-0905-526306594
  • JungOGechterJLWunderCResistant hypertension? assessment of adherence by toxicological urine analysisJ Hypertens20133176677410.1097/HJH.0b013e32835e228623337469
  • LawsonAJShipmanKEGeorgeSDasguptaIA novel ‘Dilute-and-shoot’ liquid chromatography–tandem mass spectrometry method for the screening of antihypertensive drugs in urineJ Anal Toxicol201640172710.1093/jat/bkv10226333988
  • GuptaPPatelPTomaszewskiMMeasurements of Antihypertensive Medications in Blood and UrineBurnierMDrug Adherence in Hypertension and Cardiovascular Protection Updates in Hypertension and Cardiovascular ProtectionChamSpringer201829
  • TurnerRMFontanaVBaylissMWhalleySSantoyo CastelazoAPirmohamedMDevelopment, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohortJ Pharm Biomed Anal201815927228110.1016/j.jpba.2018.06.06230005242
  • GonzalezOAlonsoRMFerreirósNWeinmannWZimmermannRDresenSDevelopment of an LC–MS/MS method for the quantitation of 55 compounds prescribed in combined cardiovascular therapyJ Chromatogr B201187924325210.1016/j.jchromb.2010.12.007
  • BerniehDLawsonGTannaSQuantitative LC-HRMS determination of selected cardiovascular drugs, in dried blood spots, as an indicator of adherence to medicationJ Pharm Biomed Anal201714223224310.1016/j.jpba.2017.04.04528525790
  • TannaSAlalaqiABerniehDLawsonGVolumetric absorptive microsampling (VAMS) coupled with high-resolution, accurate-mass (HRAM) mass spectrometry as a simplified alternative to dried blood spot (DBS) analysis for therapeutic drug monitoring of cardiovascular drugsClin Mass Spectrom20181018
  • HassallDBrealeyNWrightWHair analysis to monitor adherence to prescribed chronic inhaler drug therapy in patients with asthma or COPDPulm Pharmacol Ther201851596410.1016/j.pupt.2018.07.00129981458
  • KubáňPForetFExhaled breath condensate: determination of nonvolatile compounds and their potential for clinical diagnosis and monitoring. A reviewAnal Chim Acta201380511810.1016/j.aca.2013.07.04924296139
  • KhoubnasabjafariMRahimpourEJouybanAExhaled breath condensate as an alternative sample for drug monitoringBioanalysis201810616410.4155/bio-2017-020529236512
  • BurnsADLaneDColeRPatelPGuptaPCardiovascular medication stability in urine for non-adherence screening by LC–MS-MSJ Anal Toxicol2018bky090
  • GuptaPPatelPŠtrauchBBiochemical screening for non-adherence is associated with blood pressure reduction and improvement in adherenceHypertension2017701042104810.1161/HYPERTENSIONAHA.117.0963128847892
  • PittJJPrinciples and applications of liquid chromatography-mass spectrometry in clinical biochemistryClin Biochem Rev2009301919224008
  • LeungKSFongBMLC-MS/MS in the routine clinical laboratory: has its time come?Anal Bioanal Chem20144062289230110.1007/s00216-013-7542-524337187
  • van SchoonhovenAVvan AsseltADITomaszewskiMCost-utility of an objective biochemical measure to improve adherence to antihypertensive treatmentHypertension20187251117112410.1161/HYPERTENSIONAHA.118.1122730354817
  • ChatterjeeJSFrom compliance to concordance in diabetesJ Med Ethics200632950751010.1136/jme.2005.01213816943329
  • ForbesCADeshpandeSSorio-VilelaFA systematic literature review comparing methods for the measurement of patient persistence and adherenceCurr Med Res Opin2018341613162510.1080/03007995.2018.147774729770718
  • BruntonLLChabnerBAKnollmannBCGoodman & Gilman’s the Pharmacological Basis of Therapeutics12 edNew YorkMcGraw-Hill2011
  • HamdidoucheIJullienVBoutouyriePBillaudEAziziMLaurentSDrug adherence in hypertension: from methodological issues to cardiovascular outcomesJ Hypertens20173561133114410.1097/HJH.000000000000129928306634